Neuronetics’ Neurostar receives FDA approval
The Food and Drug Administration (FDA) has given the approval to Neuronetics Inc.’s Neurostar [a transcranial magnetic stimulation (TMS) device] for use in the treatment of depression. The non-invasive tool stimulates the brain by transmitting magnetic pulses to the skull. The device will help the adult patients who have not benefited from anti-depressants. Also, this therapy has no risks as associated with electric shock therapy and surgically implanted electrodes.
- Ranbaxy receives provisional FDA nod for generic Nexium
- Spiration, Inc’s IBV® Valve System receives HDE approval from FDA
- Roxane Receives FDA Approval For Anastrozole Tablets
- Orchid receives FDA nod for generic Kytril
